Zongertinib
- Generic Name
- Zongertinib
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
Phase 1
Recruiting
- Conditions
- Non-Small Cell Lung CancerNeoplasm Metastasis
- Interventions
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 554
- Registration Number
- NCT04886804
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸City of Hope-Duarte-56419, Duarte, California, United States
🇺🇸City of Hope - Seacliff, Huntington Beach, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath